KeenMind®
CLINICALLY RESEARCHED

An Acute, Double-Blind, Placebo-Controlled Cross-over Study of 320 mg and 640 mg Doses of Bacopa monnieri (CDRI 08™) on Multitasking Stress Reactivity and Mood

Abstract: Preclinical work on Bacopa monnieri (BM) has identified a number of acute nootropic, and adaptogenic effects of BM, as well as on nervousness and stress, that may also co-occur in humans. This double-blind, placebo-controlled cross-over study assessed the acute effects of a specific extract of BM (KeenMind, CDRI 08™) in normal healthy participants during completion of a multitasking framework (MTF).

Methods: Seventeen healthy volunteers completed the MTF, at baseline, then 1 h and 2 h after consuming a placebo, 320 mg KeenMind and 640 mg of KeenMind. Outcome measures included cognitive outcomes from the MTF, with scores for alertness, calm, contentedness, nervousness and stress, and cortisol levels.

Results: Positive cognitive effects, notably at both 1 h post and 2 h post KeenMind on tasks, suggesting an earlier nootropic effect of KeenMind. Positive mood effects and reduction in cortisol levels, pointing to a physiological mechanism for stress reduction. Acute KeenMind supplementation produced some adaptogenic and nootropic effects.

Conclusions: It was concluded that acute KeenMind supplementation produced some adaptogenic and nootropic effects that need to be replicated in a larger sample and in isolation from stressful cognitive tests in order to quantify the magnitude of these effects.

* Benson S et al. 2013. An Acute, Double-Blind, Placebo-Controlled Cross-over Study of 320 mg and 640 mg Doses of Bacopa monnieri (CDRI08) on Multitasking Stress Reactivity and Mood. Phytother. Res., Published online DOI: 10.1002/ptr.5029.

Go back to Clinical and Scientific Studies